UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 164

Sortiert nach

86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S30-S30

2013

Volltextzugriff (PDF)

2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S1-S1

2015

Volltextzugriff (PDF)

8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S4

2016

Volltextzugriff (PDF)

7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S3

2016

Volltextzugriff (PDF)

7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S4-S4

2017

Volltextzugriff (PDF)

2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S1-S1

2014

Volltextzugriff (PDF)

211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S78-S78

2014

Volltextzugriff (PDF)

5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S2-S2

2015

Volltextzugriff (PDF)

7 Targeting neuropilin-1 in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S3-S3

2013

Volltextzugriff (PDF)

8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S3-S3

2013

Volltextzugriff (PDF)

6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S2-S3

2013

Volltextzugriff (PDF)

6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S3

2016

Volltextzugriff (PDF)

4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S2-S2

2016

Volltextzugriff (PDF)

2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S1-S2

2017

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S41-S41

2014

Volltextzugriff (PDF)

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S1017

2022

Volltextzugriff (PDF)

80 Epigenetic readers and writers as therapeutic targets in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S30-S30

2014

Volltextzugriff (PDF)

4 Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S2-S2

2014

Volltextzugriff (PDF)

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S4-S4

2014

Volltextzugriff (PDF)

5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S2-S3

2014

Volltextzugriff (PDF)

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

Annals of oncology, 2021-12, Vol.32, p.S1380

2021

Volltextzugriff (PDF)

4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S2-S2

2015

Volltextzugriff (PDF)

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S25-S25

2016

Volltextzugriff (PDF)

5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S2-S3

2016

Volltextzugriff (PDF)

56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S26-S26

2017

Volltextzugriff (PDF)

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(163)

Publikationsform

Artikel
(163)
Dissertationen
(1)

Sprache

Englisch
(164)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(82)
Pulmonary/respiratory
(76)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(29)
Oncology
(28)
Biological And Medical Sciences
(18)
Female
(18)
Medical Sciences
(16)
Aged
(15)
Male
(15)
Middle Aged
(14)
Adult
(12)
Chemotherapy
(11)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Lung Neoplasms - Pathology
(9)
Pneumology
(9)
Prognosis
(9)
Tumors Of The Respiratory System And Mediastinum
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma

2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer

8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells

7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC

7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system

2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study

5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines

7 Targeting neuropilin-1 in non-small cell lung cancer

8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC

6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques

6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC

4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC

2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

80 Epigenetic readers and writers as therapeutic targets in malignant pleural mesothelioma

4 Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential

56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma

Suchergebnisse filtern